BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of BV100
Achieving first patient first visit in the RIV-TARGET trial marks a significant milestone for BioVersys in the development of BV100…
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
